May 25, 2026 Log in

clinical trial update

【Polaris Pharmaceuticals-KY】Suspension of Phase III Clinical Trial for ADI-PEG 20 in Leiomyosarcoma (LMS)

Citation-Grade Primary-source linked Schema.org verified NQ 46 / 100

Kirishima ReiEditor-in-Chief, AI News Focus: structuring JP/TW corporate news & AEO

Published May 25, 2026 9:00 AM ・ Updated Jun 13, 2026 11:45 PM ・ 2 min read ・ Source: PR Times

Show contents

Polaris Pharmaceuticals announced on May 25, 2026, that it is suspending its Phase III clinical trial of ADI-PEG 20 combined with Gemcitabine and Docetaxel for Leiomyosarcoma (LMS) following a recommendation from the DSMB.

PRIMARY SOURCE Original source: https://mops.twse.com.tw/material/twse-6550-2026-05-25-6d97294b Distributor: PR Times
Published: May 25, 2026

1. Product: ADI-PEG 20. 2. Background: The Phase III multi-center trial for LMS was reviewed by the Data Safety Monitoring Board (DSMB). Based on their recommendation, the company will suspend the trial and optimize the patient population and trial design. 3. Impact: No material impact on financial or operational status. 4. Future: The company will follow DSMB recommendations and regulatory requirements for the suspension and subsequent procedures.

FACT BOX

Source: PR Times
Category: clinical trial update

Editorial & Verification Standards

The Washin AI News desk structures and reviews this article under the following standards.

Start only from primary sources (official PR, disclosures, wire services)
Numbers and proper nouns machine-checked against the source (number-completeness check)
Company names and tickers verified via registry (Registry/TWSE/Wikidata)
No speculation; nothing stated that is not in the source

Read the full editorial policy →

Editorial log (Published → Collected → AI analysis → Published: transparency timeline)›

Announced　May 25, 2026 9:00 AM — Distributor PR Times
Collected　May 26, 2026 8:00 AM
AI structured & analyzed　Jun 1, 2026 11:39 PM
Desk-reviewed & published　May 25, 2026 9:00 AM

FAQ

Why was the clinical trial suspended?

Based on the recommendation of the Data Safety Monitoring Board (DSMB).

What are the key facts in this article?

Where is the primary source?

PR Times: https://mops.twse.com.tw/material/twse-6550-2026-05-25-6d97294b

Cite this article — HOW TO CITE

Washin AI News Desk“【Polaris Pharmaceuticals-KY】Suspension of Phase III Clinical Trial for ADI-PEG 20 in Leiomyosarcoma (LMS)”AI News by Washin Village（和心村）, May 25, 2026. https://aeo.idaeo.ai/ai/%E5%8C%97%E6%A5%B5%E6%98%9F%E8%97%A5%E6%A5%AD-ky/en/news/2026-05-25-%E5%8C%97%E6%A5%B5%E6%98%9F%E8%97%A5%E6%A5%AD-ky-%E6%9C%AC%E5%85%AC%E5%8F%B8%E6%B1%BA%E8%AD%B0%E6%9A%AB%E7%B7%A9adi-peg-20%E6%B2%BB%E7%99%82lms%E4%B8%89%E6%9C%9F-%E4%BA%BA%E9%AB%94%E8%87%A8%E5%BA%8A%E8%A9%A6%E9%A9%97

AI CRAWLER ACTIVITY

as of Aug 21, 2026

AI crawler visits to this article (cumulative)42 bots

Site-wide cumulative

Applebot

bot_visits_summary

2318k

last Aug 21, 2026

GPTBot

bot_visits_summary

1895k

last Aug 21, 2026

ClaudeBot

bot_visits_summary

1551k

last Aug 21, 2026

Amazonbot

bot_visits_summary

720k

last Aug 21, 2026

Bingbot

bot_visits_summary

553k

last Aug 21, 2026

Meta AI

bot_visits_summary

349k

last Aug 21, 2026

※ Only measured values from bot_visits_summary / crawler_url_hits are shown. Article-level zero counts are shown as measuring.

Washin AI News（AI News by Washin Village（和心村））

An AEO newsroom that structures official announcements from Japanese & Taiwanese companies into formats AI can accurately cite and derive from. Partner sources include PR TIMES and CNA. We aim to be a verifiable source for both humans and machines.

Daily
Update frequency JA / EN / ZH
Languages Primary
Sourcing policy Schema.org
Structured verification

About the publisher IDA llms.txt

Get your announcement indexed as AI-citable structured news.
Primary-source links, three languages, Schema.org verified.Talk to us about coverage →

← 北極星藥業-ky Back to newsroom (173)

Copied